KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $18.0 million.

  • Emergent BioSolutions' Share-based Compensation rose 108.70% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 14.12%. This contributed to the annual value of $18.0 million for FY2024, which is 22.08% down from last year.
  • Emergent BioSolutions' Share-based Compensation amounted to $18.0 million in FY2024, which was down 22.08% from $23.1 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Share-based Compensation ranged from a high of $51.8 million in FY2020 and a low of $18.0 million during FY2024.
  • Moreover, its 3-year median value for Share-based Compensation was $23.1 million (2023), whereas its average is $28.7 million.
  • In the last 5 years, Emergent BioSolutions' Share-based Compensation surged by 94.01% in 2020 and then plummeted by 48.78% in 2023.
  • Emergent BioSolutions' Share-based Compensation (Yearly) stood at $51.8 million in 2020, then fell by 18.15% to $42.4 million in 2021, then climbed by 6.37% to $45.1 million in 2022, then tumbled by 48.78% to $23.1 million in 2023, then decreased by 22.08% to $18.0 million in 2024.